Effect of chronic neutral endopeptidase inhibition on cardiac hypertrophy after experimental myocardial infarction

Japanese Circulation Journal

Volumn 62, Issue 9, 1998, Pages 680-686

  Yoshida, Kazunori ^a   Yasujima, Minora ^b   Casley, David J ^c   Johnston, Colin I ^c  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Autoradiography; Candoxatril; Cardiac hypertrophy; Myocardial infarction; Neutral endopeptidase

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CANDOXATRIL; CANDOXATRILAT; MEMBRANE METALLOENDOPEPTIDASE; N (1 CARBOXY 3 PHENYLPROPYL)PHENYLALANYLISOSERINE; SCH 47896; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; ENZYME INHIBITION; HEART HYPERTROPHY; HEART INFARCTION; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ATRIAL NATRIURETIC FACTOR; CARDIOMEGALY; DRUG EVALUATION, PRECLINICAL; HEMODYNAMIC PROCESSES; INDANS; KIDNEY; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; NEPRILYSIN; PROPIONATES; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR REMODELING;

EID: 0031687667     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.62.680     Document Type: Article

References (44)

1. Mckee PA, Castelli WP, McNamara PM, Kannel WB: The natural history of congestive heart failure: The Framingham study. N Engl J Med 1971; 285: 1441-1446
2. Franciosa JA, Wilen M, Ziesche S, Cohn JN: Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1983; 5: 831-836
3. Cohn JN, Levine TB, Francis GS, Goldsmith S: Neurohumoral control mechanisms in congestive heart failure. Am Heart J 1981; 102: 509-514
4. Francis GS: Neurohumoral mechanisms involved in congestive heart failure. Am J Cardiol 1985; 55: 15-21A
5. Needleman P, Greenwald JE: Atriopeptin: A cardiac hormone intimately involved in fluid, electrolyte and blood pressure homeostasis. N Engl J Med 1986; 314: 828-834
6. Lang RE, Unger T, Ganten D: Atrial natriuretic peptide: a new factor in blood pressure control. J Hypertens 1987; 5: 255-271
7. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, et al: Atrial natriuretic factor in normal subject and heart failure patients. J Clin Invest 1986; 787: 1362-1374
8. Saito Y, Nakao K, Nishimura K, Sugawara A, Okumura K, Obata K, et al: Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: Beneficial effect on left ventricular function. Circulation 1987; 76: 115-124
9. Olins GM, Spear KL, Siegel NR, Zurcher-Neely HA: Inactivation of atrial natriuretic factor by the renal brush border. Biochim Biophys Acta 1987; 901: 97-100
10. Stephenson SL, Kenny AJ: The hydrolysis of α-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J 1987; 243: 183-187
11. Sonnenberg JL, Sakane Y, Jeng AY, Koehn JA, Ansell JA, Wennogle LP, et al: Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptide 1988; 9: 173-180
12. Northridge DB, Jardine AG, Alabaster CT, Barclay PL, Connell JMC, Dargie HJ, et al: Effect of UK69578: A novel atriopeptidase inhibitor. Lancet 1989; 2: 591-593
13. Northridge DB, Jardine AG, Findlay IN, Archibald M, Dilly SG, Dargie HJ: Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure. Am J Hypertens 1990; 3: 682-687
14. Helin K, Tikkanen I, Tikkanen T, Saijonmaa O, Sybertz EJ, Vemulapalli S, et al: Prolonged neutral endopeptidase inhibition in heart failure. Eur J Pharmacol 1991; 198: 23-30
15. Fitzpatrick MA, Rademaker MT, Charles CJ, Yandle TG, Espiner EA, Ikram H, et al: Acute hemodynamic, hormonal, and renal effects of neutral endopeptidase inhibition in ovine heart failure. J Cardiovasc Pharmacol 1992; 19: 635-640
16. Winter RJD, Zhao L, Krausz T, Hughes JMB: Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia. Am Rev Respir Dis 1991; 144: 1342-1346
17. Monopoli A, Ongini E, Cigola E, Olivetti G: The neutral endopeptidase inhibitor, SCH34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992; 20: 496-504
18. Eaton LW, Weiss JL, Bulkley BH, Garrison JB, Weisfeld ML: Regional cardiac dilatation after acute myocardial infarction: recognition by two-dimensional echocardiography. N Engl J Med 1979; 300: 57-62
19. Hammermeister KE, DeRouen TA, Dodge HT: Variables predictive of survival in patients with coronary disease: selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation 1979; 59: 421-430
20. White HD, Norris RM, Brown MA, Brandt PWY, Whitlock RML, Wild CJ: Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76: 44-51
21. Pfeffer JM, Pfeffer MA, Braunwald E: Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57: 84-95
22. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P: Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985; 72: 406-412
23. Tsunoda K, Mendelsohn FAO, Sexton PM, Chai SY, Hodsman GP, Johnston CI: Decreased atrial natriuretic peptide binding in renal medulla in rats with chronic heart failure. Circ Res 1988; 62: 155-161
24. Kohzuki M, Kanazawa M, Yoshida K, Kamimoto M, Xue-Min Wu, Zhong-Li Jiang, et al: Cardiac angiotensin converting enzyme and endothelin receptor in rats with chronic myocardial infarction. Jpn Circ J 1996; 60: 972-980
25. Fishbein MC, Maclean D, Maroko PR: Experimental myocardial infarction in rat. Am J Pathol 1978; 90: 57-70
26. Kanazawa M, Casley DJ, Sybertz EJ, Haslanger MF. Johnston CI: Localization and characterization of neutral metalloendopeptidase (EC3. 4. 24. 11), the degradative enzyme for atrial natriuretic peptide, in rat kidney using ȧ radioiodinated neutral metalloendopeptidase inhibitor. J Pharmacol Exp Ther 1992; 261: 1231-1237
27. Marie C, Mossiat C, Gros C, Monteil T, Bralet J: Effect of prolonged inhibition of neutral endopeptidase on cardiac hypertrophy in rats with myocardial infarction. Cardiovasc Drugs Ther 1996; 10: 593-598
28. Bralet J, Marie C, Mossiat C, Lecomte JM, Gros C, Schwartz JC: Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. J Pharmacol Exp Ther 1994; 270: 8-14
29. Marie C, Mossiat C, Lecomte JM, Schwartz JC, Bralet J: Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction. J Pharmacol Exp Ther 1995; 275: 1324-1331
30. Richards AM, Wittert G, Espiner EA, Yandle TG, Frampton C, Ikram H: Prolonged inhibition of endopeptidase 24.11 in normal man: renal, endocrine and haemodynamic effects. J Hypertens 1991; 9: 955-962
31. Murohara Y, Johnston CI: Effect of neutral endopeptidase inhibition in rats with congestive heart failure. Clin Exp Pharmacol Physiol 1992; 19: 380-383
32. Cavero PG, Margulies KB, Winaver J, Seymour AA, Delaney NG, Burnett JC Jr: Cardiorenal action of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation 1990; 82: 196-201
33. Napier MA, Vandlen G, Albers-Schonberg G, Nutt RF, Brady EH: Specific membrane receptors for atrial natriuretic factor in renal and vascular tissues. Proc Nail Acad Sci USA 1984; 81: 5946-5950
34. Chai SY, Sexton PM, Allen AM, Figdor R, Mendelsohn FAO: In vitro autoradiographic localization of ANP receptors in rat kidney and adrenal gland. Am J Physiol 1986; 250: F753-757
35. Maack T: Receptors of atrial natriuretic factor. Annu Rev Physiol 1992; 54: 11-27
36. Koller KJ, Goeddel DV: Molecular biology of the natriuretic peptides and their receptors. Circulation 1992; 86: 1081-1088
37. Sonnenberg H, Honrath U, Wilson DR: In vitro microperfusion of inner medullary collecting duct in rats: effect of amiloride and ANF. Am J Physiol 1990; 259: F222-226
38. Richards M, Espiner E, Frampton C, Ikram H, Yandle T, Sopwith M, et al: Inhibition of endopeptidase EC 24.11 in humans. Hypertension 1990; 16: 269-276
39. Erdös EG, Skidgel RA: Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989; 3: 145-151
40. Vijayaraghavan J, Scicli AG, Carretero OA, Slaughter C, Moomaw C, Hersh LB: The hydrolysis of endothelin by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem 1990; 265: 14150-14155
41. McMahon EG, Palomo MA, Moore WM, McDonald JF, Stern MK: Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro. Proc Natl Acad Sci USA 1991; 88: 703-707
42. Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, Frampton C: Effect of inhibition of endopeptidase 24.11 on response to angiotensin II in human volunteers. Circ Res 1992; 71: 1501-1507
43. Abassi ZA, Tate JE, Colomb E, Keiser HR: Role of neutral endopeptidase in the metabolism of endothelin. Hypertension 1992; 20: 89-95
44. Margulies KB, Hildebrand FL Jr, Lerman A, Perrella MA, Burnett JC Jr: Increased endothelin in experimental heart failure. Circulation 1990; 82: 2226-2230